TY - JOUR
T1 - Development of a new easy complementation assay for DNA repair deficient human syndromes using cloned repair genes
AU - Carreau, Madeleine
AU - Eveno, Eric
AU - Quilliet, Xavier
AU - Chevalier-lagente, Odile
AU - Benoit, Annie
AU - Tanganelli, Bianca
AU - Stefanini, Miria
AU - Vermeulen, Wim
AU - Hoeijmakers, Jan H.J.
AU - Sarasin, Alian
AU - Mezzina, Mauro
N1 - Funding Information:
This work was supported by grants from the Association pour la Recherche sur le Cancer (ARC, Villejuif, France, grant no. 2083), the Ligue Nationale Francaise contre le Cancer (LNFCC, Paris, France), the Fondation de France (Paris, France), the European Science Foundation (ESF, Strasbourg, France), GEFLUC (Marseille, France), Cooperation Progrm 'Galileo' (Rome, Italy and Paris, France) and the Associazione Italiana per la Ricerca sul Cancro. Dr M.Carreau is a postdoctoral fellow of the Association pour la Recherche sur le Cancer (Villejuif, France). We wish to thank Dr D.Hunting for critical comments.
PY - 1995/5
Y1 - 1995/5
N2 - Nucleotide excision repair (NER)-deficient human cells have been assigned so far to a genetic complementation group by a somatic cell fusion assay and, more recently, by microinjection of cloned DNA repair genes. We describe a new technique, based on the host cell reactivation assay for the rapid determination of the complementation group of NER-deficient xeroderma pigmentosum (XP), Cockayne's syndrome (CS) and photosensitive trichothiodystrophy (TTD) human cells by contransfection of a UVirradiated reporter plasmid with a second vector containing a cloned repair gene. Expression of the reporter gene, either chloramphenicol acetyltransferase (CAT) or luciferase, reflects the DNA repair ability restored by the introduction of the appropriate repair gene. All genetically characterized XP, CS and TTD/XP-D cells tested failed to express the UV-irradiated reporter gene, this reflecting their NER defeciency whereas contransfection with the repair plasmid expressing a gene specific for the given complementation group increased the enzyme activity to the level reached by normal cells. Selective recovery of both reporter enzyme activities was observed after contransfection with the XPC gene for the XP17VI cells and with the XPA gene for both XP18VI and XP19VI cells. Using this method, we assigned three new NER-deficient human cells obtained from patients presenting clinical symptoms described as classical XP group A (XP18VI and XP19VI)and XP group C (XP17VI). Therefore, this technique increases the range of methods now available to determine the complementation group of new NER deficient patients with the advantage, unlike the somatic cell fusion assay or the microinjection procedure, of being simple, rapid, and inexpensive.
AB - Nucleotide excision repair (NER)-deficient human cells have been assigned so far to a genetic complementation group by a somatic cell fusion assay and, more recently, by microinjection of cloned DNA repair genes. We describe a new technique, based on the host cell reactivation assay for the rapid determination of the complementation group of NER-deficient xeroderma pigmentosum (XP), Cockayne's syndrome (CS) and photosensitive trichothiodystrophy (TTD) human cells by contransfection of a UVirradiated reporter plasmid with a second vector containing a cloned repair gene. Expression of the reporter gene, either chloramphenicol acetyltransferase (CAT) or luciferase, reflects the DNA repair ability restored by the introduction of the appropriate repair gene. All genetically characterized XP, CS and TTD/XP-D cells tested failed to express the UV-irradiated reporter gene, this reflecting their NER defeciency whereas contransfection with the repair plasmid expressing a gene specific for the given complementation group increased the enzyme activity to the level reached by normal cells. Selective recovery of both reporter enzyme activities was observed after contransfection with the XPC gene for the XP17VI cells and with the XPA gene for both XP18VI and XP19VI cells. Using this method, we assigned three new NER-deficient human cells obtained from patients presenting clinical symptoms described as classical XP group A (XP18VI and XP19VI)and XP group C (XP17VI). Therefore, this technique increases the range of methods now available to determine the complementation group of new NER deficient patients with the advantage, unlike the somatic cell fusion assay or the microinjection procedure, of being simple, rapid, and inexpensive.
UR - https://www.scopus.com/pages/publications/0029024696
U2 - 10.1093/carcin/16.5.1003
DO - 10.1093/carcin/16.5.1003
M3 - Article
C2 - 7767957
AN - SCOPUS:0029024696
SN - 0143-3334
VL - 16
SP - 1003
EP - 1009
JO - Carcinogenesis
JF - Carcinogenesis
IS - 5
ER -